YOLFTbeta
Green Cross Lab Cell Corporation

Green Cross Lab Cell Corporation

144510 · KQ · Healthcare / Diagnostics & Research

10,210.00KRW+150.00 (+1.49%)

Price History

Full chart

Market Stats

Previous Close10,060.00
Open10,240.00
Day Range10,150.00 – 10,470.00
52-Week Range11,610.00 – 28,450.00
Volume14.51K
Market Cap217.14B
P/E (TTM)0.00
Forward P/E0.00
Dividend Yield0.00%
Beta0.58
50-Day Avg14,071.40
200-Day Avg20,048.05

About

GC Cell Corporation develops cell therapy products. It also provides cell banking, sample inspection, clinical trial, and bio logistics services. Its main product is Immuncell-LC. GC Cell Corporation has strategic agreement with Lukas Biomedical Co., Ltd. to develop Cell therapy. The company was formerly known as Green Cross Lab Cell Corporation and changed its name to GC Cell Corporation in November 2021. GC Cell Corporation was founded in 2011 and is based in Yongin-si, South Korea.

Company Details

  • SectorHealthcare
  • IndustryDiagnostics & Research
  • CEOMr. Jai-Wang Kim
  • Employees674
  • Headquarters107, Ihyeon-ro, Yongin-si, South Korea, 16924, Korea
  • Websitehttps://www.gccell.com

Leadership

  • Mr. Jai-Wang KimCEO & Chairman · b. 1966
  • Won Sung-YongCEO & Director · b. 1971

Financials

Income Statement

Currency: KRW2015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue34.49B42.42B45.80B50.62B57.90B85.56B168.31B236.12B187.54B174.45B165.52B
Growth (%)-+22.99%+7.96%+10.53%+14.37%+47.79%+96.71%+40.29%-20.57%-6.98%-5.12%
Cost of Revenue27.23B32.16B35.59B38.38B43.49B62.27B99.61B139.17B132.41B141.36B136.55B
Gross Profit7.26B10.25B10.21B12.24B14.40B23.29B68.70B96.95B55.14B33.09B28.97B
Gross Margin21.05%24.17%22.29%24.17%24.88%27.22%40.82%41.06%29.40%18.97%17.50%
Operating Expense4.04B8.76B9.33B11.80B18.21B16.86B32.33B52.58B50.94B101.13B42.77B
Operating Income3.22B1.49B881.26M435.05M-3.81B6.43B36.37B44.36B4.19B-68.05B-13.79B
Operating Margin9.34%3.52%1.92%0.86%-6.58%7.52%21.61%18.79%2.23%-39.01%-8.33%
EBITDA-------52.61B11.58B-57.66B-250.94B
EBITDA Margin-------22.28%6.18%-33.05%-151.61%
Net Income2.26B2.33B1.06B1.00B-2.28B4.16B31.42B24.37B-174.01M-73.90B-272.86B
Net Income Margin6.55%5.49%2.31%1.98%-3.93%4.86%18.67%10.32%-0.09%-42.36%-164.85%
R&D2.73B6.38B6.63B9.56B15.11B13.96B18.49B26.43B24.68B25.21B18.02B
R&D as % of Total Revenue7.92%15.05%14.47%18.88%26.10%16.32%10.99%11.19%13.16%14.45%10.89%
Interest Expense00000247.22M559.04M2.48B3.41B4.89B4.77B
Interest Expense % of Total Revenue0.00%0.00%0.00%0.00%0.00%0.29%0.33%1.05%1.82%2.80%2.88%

Balance Sheet

Currency: KRW2015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets16.86B54.51B55.36B57.27B68.06B76.36B645.57B676.53B665.17B578.35B303.69B
Total Liabilities7.90B6.42B7.03B9.55B24.02B29.19B134.57B138.07B123.69B120.56B113.31B
Total Equity8.96B48.10B48.32B47.72B44.05B47.17B511.00B538.46B534.02B457.79B186.39B
Cash56.06M39.24B313.03K23.28B13.59B9.11B18.00B47.37B12.56B5.04B1.46B
Total Debt----5.05B5.35B-----
Net Debt------24.73B-37.05B46.95B50.15B

Cash Flow

Currency: KRW2015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow1.49B-296.65M2.86B490.92M223.04M9.09B23.91B66.42B3.67B11.34B9.19B
Investing Cash Flow-1.98B-36.35B36.33B-15.26B-10.87B-15.05B17.29B-33.72B-34.30B-10.62B-
Financing Cash Flow523.18M36.77B-791.55M-527.70M957.19M1.53B-32.39B-3.32B-4.06B-8.85B-
Capital Expenditure833.86M855.59M1.78B4.78B5.34B4.79B10.88B6.91B18.40B6.03B6.47B
Free Cash Flow-----2.95B10.19B52.64B-14.73B5.31B2.72B
Dividends Paid273.49M791.55M791.55M527.70M369.39M263.85M1.06B-5.25B1.50B-
FCF to OCF-----32.48%42.61%79.25%-401.18%46.80%29.57%
Dividend Paid to FCF-----8.93%10.36%--35.68%28.29%-

Earnings

Report DateAug 16, 2016Nov 14, 2016Jan 26, 2017Apr 25, 2017Jul 26, 2017Oct 31, 2017Mar 12, 2018Apr 27, 2018Jul 24, 2018Oct 25, 2018Feb 11, 2019Apr 30, 2019Jul 30, 2019Oct 29, 2019Feb 5, 2020Apr 28, 2020Jul 27, 2020Oct 27, 2020Feb 9, 2021May 14, 2021Jul 26, 2021Oct 25, 2021Feb 10, 2022Apr 28, 2022Jul 31, 2022Nov 1, 2022Feb 8, 2023May 12, 2023Aug 14, 2023Nov 14, 2023Mar 27, 2024May 16, 2024Aug 14, 2024Nov 12, 2024Jan 24, 2025Apr 30, 2025Aug 12, 2025Sep 30, 2025Dec 31, 2025Apr 28, 2026Jun 30, 2026
EPS Estimate-----------------------------------------
EPS Actual102.7984.84-11.8079.5659.0225.00-63.37-1.0288.86-45.8552.95-79.3613.90-27.08-122.84-22.00229.00130.0057.60485.00154.51762.001232.741637.44225.00375.00-576.44-189.25-150.58196.13131.97-630.31-410.46683.27-4560.37-1185.46-613.28-175.29-16183.70-195.15157.46
Surprise-----------------------------------------
Timing-After-hours-After-hoursPre-marketPre-marketPre-marketAfter-hoursAfter-hoursPre-marketAfter-hours-Pre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hours--After-hours--Pre-marketAfter-hours-After-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketAfter-hoursAfter-hoursAfter-hoursPre-marketPre-marketPre-market--Pre-market-

Key Statistics & Ratios

Market Cap217.14B
Enterprise Value317.98B
Trailing P/E0.00
Forward P/E0.00
Price / Sales1.34
Price / Book1.14
Revenue (TTM)162.00B
Gross Profit (TTM)29.34B
EBITDA4.27B
Profit Margin-152.10%
Operating Margin-2.43%
Return on Equity-79.19%
Return on Assets-1.50%
Shares Outstanding15.03M
Shares Float8.27M
Beta0.58
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Dividends

20231×
100.00Dec 27, 2023
20221×
350.00Dec 28, 2022
20211×
100.00Dec 29, 2021
20201×
100.00Dec 29, 2020
20191×
25.00Dec 27, 2019
20181×
35.00Dec 27, 2018
20171×
50.00Dec 27, 2017
20161×
75.00Dec 28, 2016